INMODE LTD (INMD)
IL0011595993 - Common Stock
Overall INMD gets a fundamental rating of 7 out of 10. We evaluated INMD against 192 industry peers in the Health Care Equipment & Supplies industry. INMD has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. INMD is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings could make INMD a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year INMD was profitable.
INMD had a positive operating cash flow in the past year.
Each year in the past 5 years INMD has been profitable.
INMD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 20.30%, INMD belongs to the top of the industry, outperforming 97.92% of the companies in the same industry.
INMD's Return On Equity of 22.20% is amongst the best of the industry. INMD outperforms 95.83% of its industry peers.
With an excellent Return On Invested Capital value of 17.89%, INMD belongs to the best of the industry, outperforming 97.92% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for INMD is significantly above the industry average of 8.46%.
The 3 year average ROIC (28.25%) for INMD is well above the current ROIC(17.89%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.3% | ||
| ROE | 22.2% | ||
| ROIC | 17.89% |
ROA(3y)27.49%
ROA(5y)27.16%
ROE(3y)31.31%
ROE(5y)31.63%
ROIC(3y)28.25%
ROIC(5y)27.22%
1.3 Margins
With an excellent Profit Margin value of 38.83%, INMD belongs to the best of the industry, outperforming 99.48% of the companies in the same industry.
INMD's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 37.05%, INMD belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
INMD's Operating Margin has improved in the last couple of years.
INMD has a better Gross Margin (83.09%) than 93.75% of its industry peers.
INMD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 37.05% | ||
| PM (TTM) | 38.83% | ||
| GM | 83.09% |
OM growth 3Y4.03%
OM growth 5Y4.81%
PM growth 3Y3.39%
PM growth 5Y12.47%
GM growth 3Y-0.57%
GM growth 5Y-0.32%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so INMD is creating value.
The number of shares outstanding for INMD has been increased compared to 1 year ago.
Compared to 5 years ago, INMD has more shares outstanding
There is no outstanding debt for INMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
INMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.91
WACC9.35%
2.3 Liquidity
A Current Ratio of 13.45 indicates that INMD has no problem at all paying its short term obligations.
With an excellent Current ratio value of 13.45, INMD belongs to the best of the industry, outperforming 96.88% of the companies in the same industry.
A Quick Ratio of 12.66 indicates that INMD has no problem at all paying its short term obligations.
INMD has a better Quick ratio (12.66) than 97.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.45 | ||
| Quick Ratio | 12.66 |
3. Growth
3.1 Past
INMD shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.45%.
The Earnings Per Share has been growing by 45.76% on average over the past years. This is a very strong growth
Looking at the last year, INMD shows a decrease in Revenue. The Revenue has decreased by -1.71% in the last year.
Measured over the past years, INMD shows a very strong growth in Revenue. The Revenue has been growing by 37.48% on average per year.
EPS 1Y (TTM)-7.45%
EPS 3Y34.38%
EPS 5Y45.76%
EPS Q2Q%-38.46%
Revenue 1Y (TTM)-1.71%
Revenue growth 3Y33.65%
Revenue growth 5Y37.48%
Sales Q2Q%-24.31%
3.2 Future
Based on estimates for the next years, INMD will show a decrease in Earnings Per Share. The EPS will decrease by -1.05% on average per year.
The Revenue is expected to grow by 3.56% on average over the next years.
EPS Next Y-18.81%
EPS Next 2Y-4.94%
EPS Next 3Y-1.05%
EPS Next 5YN/A
Revenue Next Year-2.19%
Revenue Next 2Y2.7%
Revenue Next 3Y3.56%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 8.11 indicates a reasonable valuation of INMD.
98.96% of the companies in the same industry are more expensive than INMD, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 28.05. INMD is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 8.27, which indicates a very decent valuation of INMD.
98.44% of the companies in the same industry are more expensive than INMD, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of INMD to the average of the S&P500 Index (20.07), we can say INMD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.11 | ||
| Fwd PE | 8.27 |
4.2 Price Multiples
INMD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. INMD is cheaper than 98.44% of the companies in the same industry.
96.88% of the companies in the same industry are more expensive than INMD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.03 | ||
| EV/EBITDA | 2.51 |
4.3 Compensation for Growth
The excellent profitability rating of INMD may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.18
EPS Next 2Y-4.94%
EPS Next 3Y-1.05%
5. Dividend
5.1 Amount
INMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INMODE LTD
NASDAQ:INMD (5/31/2024, 7:00:02 PM)
After market: 19.29 +0.16 (+0.84%)19.13
+0.26 (+1.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.62B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.11 | ||
| Fwd PE | 8.27 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)0.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.3% | ||
| ROE | 22.2% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 37.05% | ||
| PM (TTM) | 38.83% | ||
| GM | 83.09% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 13.45 | ||
| Quick Ratio | 12.66 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-7.45%
EPS 3Y34.38%
EPS 5Y
EPS Q2Q%
EPS Next Y-18.81%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-1.71%
Revenue growth 3Y33.65%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y